The following are recent financial reports as posted by selected Utah corporations:
Qualtrics, based in Provo and Seattle, reported a net loss of $263.5 million, or 51 cents per share, for the second quarter ended June 30. That compares with a loss of $127.5 million, or 30 cents per share, for the same quarter a year earlier.
Revenue in the most recent quarter totaled $249.3 million, up from $181 million in the year-earlier quarter.
Qualtrics provides experience management technology.
“Today, the experiences companies deliver are absolutely vital to staying competitive,” Zig Serafin, CEO, said in announcing the results. “Every company is going through an experience transformation, and they’re turning to Qualtrics to help them deliver breakthrough experiences for their employees and customers. We’ve never been more relevant, which you can see in our strong Q2 results and our revenue guidance of more than $1 billion in 2021.”
Utah Medical Products
Utah Medical Products Inc., based in Salt Lake City, reported net income of $3.4 million, or 94 cents per share, for the second quarter ended June 30. That compares with $1.3 million, or 36 cents per share, in the year-earlier quarter and with $3.5 million, or 94 cents per share, during the 2019 second quarter.
Net sales in the most recent quarter totaled $12.6 million, up from $8.8 million in the year-earlier quarter and the 2019 second quarter’s $11.9 million.
Utah Medical Products, with particular interest in healthcare for women and their babies, develops, manufactures and markets a range of disposable and reusable specialty medical devices.
The company said the year-earlier figures were during a time when there were restrictions on so-called nonessential medical procedures. The second-quarter and first-half figures for 2021 “confirm that, after surviving a depression in its business in 2020, UTMD may be back on track, notwithstanding possible future restrictions on healthcare which benefits from the use of UTMD’s medical devices, or other consequences of government policies that may have a negative impact on the free market, medical device industry and small businesses in particular.”